Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over the pace of change and will be replaced by Lars Rebien Sorensen, a previous leader of the Danish drugmaker who now ...

LONDON/COPENHAGEN, Oct 24 (Reuters) - A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, rattling investors despite calls for ...

Novo Nordisk Chairman Helge Lund, along with several other board members, will be leaving their positions following a disagreement with the company's largest shareholder, the Novo Nordisk Foundation.

Novo Nordisk (NVO) has received approval to market its oral GLP-1 medicine Rybelsus in the U.S. to reduce the risk of major cardiovascular events such as stroke in adults with type 2 diabetes, the ...

LONDON, Oct 22 (Reuters) - Boardroom drama at Wegovy-maker Novo Nordisk (NOVOb.CO), opens new tab has laid bare the company's biggest challenge: how to better tap into America's mass market for weight ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk about how startups are looking for new ways to price ...

Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's mass market for weight-loss drugs. The Danish drugmaker that initially ...

The Court of Appeal has reinstated a claim concerning the termination of a contract for an automated border control system, which had previously been dismissed by the High Court. This project aims to ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera. BDO's First Brands Audit Painted Healthy Picture Months Before Collapse The ...

Novo Nordisk (NVO) has notified employees impacted by the drugmaker’s job cuts in the vast majority of its locations although the pace varies according to local laws, its CEO Mike Doustdar wrote in a ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...